Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Glucocorticoid-induced osteoporosis.

B P Lukert1

  • 1Division of Endocrinology, Metabolism and Genetics, University of Kansas Medical Center, Kansas City.

Southern Medical Journal
|August 1, 1992
PubMed
Summary

Long-term glucocorticoid therapy causes 30-50% osteoporosis incidence. Strategies to minimize bone loss include appropriate dosing, nutritional support, and hormone replacement therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spinal extension exercises prevent natural progression of kyphosis.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2008
Same author

Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

Arthritis and rheumatism·1999
Same author

Management of glucocorticoid-induced osteoporosis--first, do no harm: comment on the American College of Rheumatology recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis.

Arthritis and rheumatism·1997
Same author

Long-term low ascorbic acid intake reduces bone mass in guinea pigs.

The Journal of nutrition·1996
Same author

Scurvy results in decreased collagen synthesis and bone density in the guinea pig animal model.

Bone·1996
Same author

Etidronate in the management of glucocorticoid-induced osteoporosis.

The American journal of medicine·1995

Area of Science:

  • Endocrinology
  • Bone Biology
  • Pharmacology

Background:

  • Glucocorticoids are widely used medications with significant side effects.
  • Osteoporosis is a major concern, affecting 30-50% of patients on long-term glucocorticoid therapy.
  • Glucocorticoid-induced bone loss disproportionately affects trabecular bone over cortical bone.

Purpose of the Study:

  • To elucidate the multifactorial causes of glucocorticoid-induced bone loss.
  • To outline strategies for minimizing bone loss in patients receiving glucocorticoids.

Main Methods:

  • Review of existing literature on glucocorticoid effects on bone metabolism.
  • Analysis of factors contributing to reduced calcium absorption and increased excretion.
  • Examination of hormonal changes and direct effects on bone formation.

Main Results:

  • Glucocorticoids impair calcium absorption, increase urinary calcium excretion, decrease gonadal hormone production, and inhibit bone formation.
  • Bone loss is characterized by rapid trabecular bone depletion.
  • Several interventions can mitigate bone loss.

Conclusions:

  • Minimizing glucocorticoid dose and duration, optimizing nutrition and physical activity, and managing hormonal deficiencies are key.
  • Pharmacological interventions like calcitonin or bisphosphonates may be considered.
  • Maintaining adequate vitamin D levels and utilizing hormone replacement therapy are crucial.

Related Experiment Videos